HEALEY ALS Platform Trial

Weekly Q&A - July 29, 2021

















Healey Center

Sean M. Healey & AMG Center for ALS at Mass General







































Guest Speaker

Hristelina Ilieva, MD, PhD
Thomas Jefferson, PA
Platform Trial Site Investigator





- Piera Pasinelli, PhD -
 - Director
- Hristelina Ilieva, MD, PhD -
 - Clinical Director and PI of Healey Platform Trial
- Davide Trotti, PhD
 - Research Director
- Jessica Rinaldi -
 - Associate Director of Clinical Research
- > Stephanie Hansen, Madeleine Singson, Sofia Nastri, Christopher Hague, Melissa Warren
 - Clinical Research Team

Jefferson Weinberg ALS Center

4 RESEARCH LABORATORIES (BASIC-TRANSLATIONAL)

INTER-DISCIPLINARY CLINIC

(Standard of care +
Pulmonology; Physiatry;
Palliative Care; Research Education
ALSA Staff)

CLINICAL RESEARCH


SOCIAL WORK



Healey Platform Trial

- Our site started enrolling patients in August of 2020, and enrollment is still ongoing.
- Our site currently has 11 patients participating in this trial.
 - ▶ 3 on Regimen A, 3 on Regimen B, 4 on Regimen C, 1 on Regimen D.
 - > 5 patients have moved on to the open label extension, 6 remain on double-blind.
 - ▶ 2 patients have completed DB phase but unable to continue with OLE due to disease progression.

Perpetual Adaptive Trial Shared Placebo; Randomization Ratio 3:1 Open Label Extension (OLE) offered




Enrollment Updates (as of July 29, 2021)

- 676 individuals with ALS signed informed consent
- 534 individuals were assigned to a regimen
- 482 individuals were randomized within a regimen (active or placebo)
- 155 have entered the Open Label Extension (OLE)
- 130 individuals were randomized within Regimen A
- 149 individuals were randomized within Regimen B
- 148 individuals were randomized within Regimen C
- 55 individuals were randomized within Regimen D



How to Find a Center Near You



52 sites are actively enrolling

Contact Info of Participating Sites by State



https://www.massgeneral.org/neurology/als/research/platform-trial-sites

Patient Navigator



Catherine Small Allison Bulat

Phone: 833-425-8257 (HALT ALS)

E-mail:healeyalsplatform@mgh.harvard.edu



To see whether you might qualify, view the list of eligibility criteria:

https://bit.ly/3p4PrLL



Send us webinar ideas!

- Biomarkers
- Biostatistics / Trial Design
- Get to know our sites





Upcoming Guest Speakers:

Aug 5th- TBD

Aug 12th- Michael Weiss, MD, FAAN (University of Washington, WA)

Aug 19th- Laura Foster, MD (University of Colorado, CO)

Aug 26th-TBD

For More Updates

Weekly webinars

The idea of came from our Patient Advisory Committee: we are excited to be talking with you on a weekly basis and take any questions you might have

Find the schedule and registration links on our website

https://www.massgeneral.org/neurology/als/research/platform-trial-news/

Previously: Drug mechanism of action and science webinars



Jan 21- Prilenia/Pridopidine

Feb 4 - Clene/CNM-Au8

Feb 18- Biohaven/Verdiperstat (recorded- https://bit.ly/301qdDR)

Feb 25- UCB/Zilucoplan

(<u>recorded</u>- https://bit.ly/3ad3qel)

(recorded- https://bit.ly/3jB3WWt)

(recorded- https://bit.ly/3b3cpyS)